cyrilzakka/clinical-trials huggingface dataset:
Neuromuscular and Proprioceptive Training in Football Players

The objective of this study was to determine the effect of proprioceptive and neuromuscular training on landing errors and balance of the football players. This was randomized controlled trial in which 40 football players were randomly allocated into experimental and control group. The control group followed conventional exercise plan while experimental group players were being trained under Myklebust's training program. Data were collected at baseline and after follow-up of five weeks Landing Error Score System (LESS) and Biodex Single Leg Stability (SLS) score. Data were analyzed using statistical package for social sciences (SPSS)-21.

Anterior cruciate ligament (ACL) injuries are a severe public health issue from both an economic and general wellness view. This burden will be reduced by promoting compliance and the use of injury prevention programs. To reduce injury rates, trainers, athletes, parents, and the team of sports medicine need to know the advantages of injury prevention programs. Parents and employees in sports medicine want a program that can decrease the risk of injury. Coaches and athletes are looking for a program that will also increase athletic efficiency without taking time off exercise, time that would otherwise be spent honing sport-specific abilities. Injury prevention programs in youth athletics will promote neuromuscular enhancements and create appropriate long-term techniques while instantly preparing the athlete for competition.

Various studies have been done to assess the role of proprioceptive and neuromuscular exercises on reducing incidence of ACL injury. No conclusive result has been established as yet that these type of exercises really reduce the incidence of ACL injury or not. However, it is found that by performing certain exercises there is improvement in biomechanics of jump landing as predicted by LESS score which is a reliable tool to establish risk of ACL and other lower limb injury in an athlete. Therefore the investigators have used a lower limb injury prevention program to assess its effectiveness in reducing LESS score.

Eligibility Criteria:
Inclusion Criteria:

* Male football players registered with Pakistan Sports Board, Islamabad.
* Players playing for a minimum of 20 hrs per week.
* The participant should understand and sign the informed consent form.
* Players should agree to take part in the training program for 35 days.

Exclusion Criteria:

* Players with any major neuromusculoskeletal or cardiovascular pathology in last 6 months.
* Players having any psychological issue
CMR Right Ventricular Contractile Reserve Following Lung Resection

Feasibility study investigating CMR dobutamine stress testing before and after lung resection

We hypothesise that following lung resection,

1. the subtle decrease in RV function and increase in afterload we have demonstrated at rest is associated with a marked impairment of RV function on exercise, termed impaired RV contractile reserve (RVCreserve),
2. impaired RVCreserve is associated with impaired functional capacity .

In this study we aim to assess the feasibility of dobutamine stress cardiovascular magnetic resonance (CMR) scanning to assess RVCreserve pre- and post-operatively in patients undergoing lung resection.

Additionally, we hypothesise that one lung ventilation (with and without lung resection) is associated with biomarker evidence of RV injury.We will perform peri-operative cardiac biomarkers to differentiate between the contribution of major surgery (gastrectomy, lung resection and oesophagectomy), one lung ventilation (lung resection and oesophagectomy) and lung resection on RV injury.

Eligibility Criteria:
Inclusion Criteria:

* 1) Provision of informed consent 2) Age \>16 years 3) Planned elective

  1. lobectomy lung resection or
  2. oesophagectomy surgery with one lung ventilation or
  3. gastrectomy

Exclusion Criteria:

1. Pregnancy
2. On-going participation in any investigational research which could undermine the scientific basis of the study
3. Atrial fibrillation at baseline
4. Any contraindication to

   a. CMR, i. Cardiac pacemaker, artificial heart valve, neurostimulator, cochlear implant ii. Aneurysm clips iii. Metal injuries to the eye iv. Loose metal in a part of the body b. Dobutamine stress testing as per the Society for Cardiovascular Magnetic Resonance64 i. Severe systemic arterial hypertension (≥220/120 mmHg) ii. Unstable angina pectoris iii. Severe aortic valve stenosis (peak aortic valve gradient \>60mmHg or aortic valve area \< 1cm2) iv. Complex cardiac arrhythmias including uncontrolled atrial fibrillation v. Hypertrophic obstructive cardiomyopathy vi. Myocarditis, endocarditis, or pericarditis vii. Uncontrolled heart failure
5. Lung resection specific

   1. Wedge, segmental or sub-lobar lung resection
   2. Pneumonectomy
   3. Isolated right middle lobectomy

      -
Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery

MOBILE2 is a randomized controlled trial comparing mechanical and oral antibiotic bowel preparation to mechanical bowel preparation only in patients undergoing anterior rectal resection with primary anastomosis. Primary endpoint is Comprehensive Complication Index within 30 days from surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for anterior rectal resection with primary anastomosis

Exclusion Criteria:

* Emergency operation
* Bowel obstruction
* Existing stoma
* Other reason preventing mechanical bowel preparation
* Allergy to neomycin or metronidazole
* Age \< 18 years
* Lack of co-operation

Exclusion criteria after randomization:

* Patient did not undergo surgery
* Anterior resection was not performed
* Colonic anastomosis was not performed
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).

This 3 arm study will compare the prophylactic effect of topical corticosteroids, Bepantol or placebo on hand-foot syndrome in patients receiving Xeloda for treatment of metastatic breast cancer, metastatic colorectal cancer or adjuvant treatment of colorectal cancer. Patients who have been receiving oral Xeloda for at least 5 days will be randomized to receive prophylactic treatment with either placebo, topical corticosteroids or Bepantol. The anticipated time on study treatment is until disease progression or development of hand-foot syndrome, and the target sample size is 500+ individuals.


Eligibility Criteria:
Inclusion Criteria:

* adult patients, \>=18 years of age;
* breast cancer or colorectal cancer patients;
* treated with oral Xeloda for \<=5 days;
* lack of hand-foot syndrome (palmar-plantar erythrodysesthesia).

Exclusion Criteria:

* existence of clinical symptoms suggesting hand-foot syndrome;
* use of doxorubicin, 5-FU and/or cytarabine for last 3 months;
* diabetes mellitus.
AI-Based IMT Study

Cerebro-vascular and heart diseases have together ranked 4th and 5th place in the 2022 top ten leading causes of death in Hong Kong, taking up more than 15% of the total in an unceasing trend. While conventional carotid ultrasound imaging is nothing short of comprehensive, it is highly operator-dependent and is worsened by the shortage of medical staff in Hong Kong.

The seemingly long queue for the expensive health screenings has put the high-risk groups, including but not limited to the elderly, in a vulnerable position as they can hardly perform regular and frequent check-ups.

In light of this, our team is determined to research a solution that is conducive to the preventive healthcare of strokes and cardiovascular diseases through one of the newly proposed devices: PyrocksTM Tag Lite.

This study aims to investigate an approach for developing a robust deep learning model for analysing ultrasound images and incorporate the model into our established prototype to perform intima-media thickness measurement and risk assessment.

Main points that the clinical trial can assist in solving the existing problem:

The acquisition procedures are non-invasive, painless, and safe for the participants. Clinical trials \& test data will assist in testing and training our neural network model.


Eligibility Criteria:
Inclusion Criteria:

* Adults (over the age of 18 years)(with Elderlies (over the age of 65 years) more preferred)
* Patients with cardiovascular diseases (CVD), including current smokers or diagnosed with diabetes, dyslipidaemia, coronary artery disease, cerebrovascular disease, hypertension, atherosclerotic cardiovascular disease, high blood pressure, high BMI index and those under antihypertensive treatment.

Exclusion Criteria:

* none
Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids

The current literature suggests that zinc supplementation may increase the duration of botulinum toxin; however, each study had their limitations. Further, no one has studied the effect of zinc supplementation for botulinum toxin treatment of the forehead. The purpose of this study is to evaluate the effect of zinc supplementation on frontalis muscle denervation by objectively assessing the degree of forehead rhytids and movement of the eyebrows.


Eligibility Criteria:
Inclusion Criteria:

Any patient older than 18 years old who desires botulinum toxin injection to decrease forehead rhytids

Exclusion Criteria:

* Allergy to any components of zinc citrate or botulinum toxin
* inflammation or infection at site of injection
* patients using anticholineresterase or other agents interfering with neuromuscular transmission
* patients with any medical condition that can affect frontalis function (Bell's palsy, Möbius syndrome, Hemifacial microsomia, CHARGE syndrome, stroke, etc)
* patients with any prior trauma that could have potentially injured the frontalis muscle
* patients dependent on intact facial movements and expressions for their livelihood (actors, singers, musicians, etc)
A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding colorectal cancer.

The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding colorectal cancer.

Eligibility Criteria:
Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
2. Male or female patients of any age (interest is given to children to compare with mothers).
3. Diagnosis of colorectal cancer

Exclusion Criteria:

1. Refusal to sign informed consent form
2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
3. Postoperative stoma, ostomy, or ileoanal pouch
4. Participation in any experimental drug protocol within the past 12 weeks
5. Treatment with total parenteral nutrition
6. Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
7. Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
Activation Technique in cVEMPs

This study will investigate two different techniques used for eliciting sternocleidomastoid (SCM) muscle contraction. Sustained contraction of the SCM muscle is necessary for accurate recording of cervical vestibular evoked myogenic potentials (cVEMPs). These responses are used clinically to assess the function of structures within the vestibular system.

The British Society of Audiology (BSA) guidelines recommend the head turn and head raise techniques as effective methods for eliciting SCM contraction. However, they do not recommend which technique to employ, leaving that to the discretion of the clinician. The purpose of this study is to determine which activation technique to recommend in the local standard operating procedure on cVEMP testing developed by the Audiology and Vestibular Function Testing service based at the Royal Liverpool University Hospital.

Healthy volunteers will be recruited to the study. The study will be conducted at the Royal Liverpool University Hospital, Liverpool, UK.

The participants will each be invited to attend one appointment in which they will undergo cVEMP testing, performed using each activation technique in turn. After testing the participants will be asked to complete a questionnaire in which they will comment on their experience of performing each technique and assign each a tolerability rating.


Eligibility Criteria:
Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study.
* Able (in the Investigators opinion) and willing to comply with all study requirements.
* Male, female or non-binary, aged 18-60 years old.

Exclusion Criteria:

* Pain, sore areas, broken skin at the sites of contact with skin electrodes
* Devices, e.g. cochlear implants, which may cause electrical interference

Exclusion criteria to cVEMP procedure :

* Conductive hearing loss of middle ear origin
* Sensitivity to sounds e.g. tinnitus, hyperacusis etc.
* Cervical spine problems

Exclusion criteria to tympanometry procedure :

* Occlusion of the external auditory canal
* Otorrhoea
* Otalgia
* Excessive wax
* Within two months of ear surgery
Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNEN

Small Intestinal neuroendocrine Tumors (SiNETs) incidence is rising. Most of siNETs primaries are localized in jejunum/ileum. At the diagnosis, 50-70% of them present either lymph node (LN) and/or liver metastases (LM). It is admitted that almost 30% of the patients present or will present primary complications. Primary complications include endoluminal obstruction and/or LN-fibrotic mesenteritis with occlusive symptoms, and less frequently haemorrhage and/or intestinal ischemia.However, it is not clear weather this affects patient with or without multiple liver metastases (LM). In this regard, many centres propose to perform primary resection even in patients presenting unresectable LM. Thus, systemic reviews suggest a possible benefit of the primary midgut siNETs resection even in patients with unresectable LM, there is no prospective randomized trial showing the benefit of primary resection in such patients especially those who are totally asymptomatic. Indeed, all retrospective published series have several limitations and the results should be therefore considered with caution.

Theoretical impact of "preventive" resection of midgut primaries in patients with unresectable LM and totally free of occlusive symptoms is controversial. Firstly, it is to avoid primary mechanical complications, and secondly to allow targeting therapeutics to the liver compartment. In this regard, in patients with synchronous unresectable LM from siNENs, ENETS, UKINETS, NANETS guidelines propose, in "a case-by-case" selective approach, the resection of the primary, while NCCN guidelines advocate to do not propose primary resection in such patient if they are free of symptoms with low tumor burden.


Eligibility Criteria:
Inclusion Criteria:

* 18 years old
* Patient with Si-NET and liver metastases considered as non-resectable
* Primary-related "asymptomatic" patient at diagnosis
* Diagnosed during the past 6 months
* No symptoms in relation with the primary or with mesenteric lesions
* Symptoms related to carcinoid syndrome allowed

Exclusion Criteria:

* None
A Cafeteria Based Study of Weight Gain Prevention

The dramatic rise in overweight and obesity during the past several decades can be explained by environmental changes that foster increased energy intake and decreased energy expenditure. There are several reasons to suggest that the most effective approach to weight gain prevention is the incorporate reduced-fat eating into an overall strategy of lowering the energy density of the diet. Our energy density manipulations will be designed to reduce both the fat content and the caloric density of foods served at a cafeteria, which serves as the "food environment" for hospital employees.


Eligibility Criteria:
Inclusion Criteria:

* works at one of the two hospitals and eats lunch in the cafeteria 2x per week
* BMI between 23 and 25

Exclusion Criteria:

* current diagnosis of a chronic disease or condition known to affect appetite or body weight
* currently taking medication known to affect appetite or body weight
* current pregnancy or plans to become pregnant within the next 24 months
* current enrollment or plans to enroll within the next 24 months in an organized weight management program
* plans to terminate employment at the hospital within the next 12 months
A First in HUman Study for Resistant Epilepsy with the Vagus Nerve StimulatiOn Device by SyneRgia MedicAl

This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM.

This is the first clinical investigation with the NAO.VNS SYSTEM from Synergia Medical.

Up to 10 patients with drug resistant epilespy, who are eligible for vagus nerve stimulation, will be included in two sites.

The total duration of the study is expected to be 36 months. Study procedures are composed of (i) baseline, (ii) implantation, (iii) titration and (iv) follow-up until 24 months.

Primary objective is to evaluate safety of the NAO.VNS SYSTEM.

Eligibility Criteria:
Inclusion Criteria:

1. Ability to understand the Informed Consent Form (ICF) and the study procedures and provide written consent or, in case of cognitive impairment, be the legal ward of a person who is able and willing to provide written consent.
2. Subjects diagnosed with Drug Resistant Epilepsy (DRE) and candidate for VNS treatment
3. Ability of subjects or, in the case of cognitive impairment, their caregiver, to accurately count seizures and complete seizure diaries.
4. Adult subjects, age ≥ 18.
5. Willingness of subjects or, in the case of cognitive impairment, their caregiver, to charge the NAO.VNS system with the Smart Charger on a weekly basis.
6. Subjects' willingness to follow the protocol procedures. For example, subject should have a careful seizure diary completion according to standard of care to ensure 8 weeks of data available by time of implant.
7. Female subjects of childbearing age using acceptable methods of birth control (abstinence considered acceptable).

Exclusion Criteria:

1. Unstable medical condition likely to precipitate seizures and make it difficult to evaluate efficacy.
2. Prior cervical vagotomy.
3. Progressive neurological disease.
4. Pregnancy.
5. Significant cardiac or pulmonary disease under treatment.
6. History of noncompliance for seizure diary completion.
7. Prior implant with vagus nerve stimulation device.
8. Current active treatment of epilepsy with cerebellar or thalamic stimulation.
9. Prior therapeutic brain surgery for epilepsy within the last 6 months prior to NAO.VNS implantation.
10. Receiving or likely to receive short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy after implantation.
11. Currently receiving another investigational treatment.
12. Patient with Vocal Cord Palsy (VCP), including unilateral, whatever the side.
13. Diabetic patients and all patients with a known vagal neuropathy.
14. Coagulation disorder, wound healing and bleeding disorder or taking anticoagulant medication (oral anticoagulants; antiplatelets (such as aspirin, ticagrelor) are allowed).
15. Patient currently participating in another clinical investigation, without explicit consent of the Sponsor (non-interventional registries are allowed).
Occurrence of Pneumocystis Pneumonia in HIV-Infected Patients and the Interference of the HAART

From the beginning of the AIDS epidemic, pulmonary pneumocystosis (PCP) has been distinguished as one of the most frequent opportunistic diseases with high morbid-mortality. As from 1996, the advent of the highly active antiretroviral therapy (HAART) has changed the characteristics of such epidemic by reducing its related diseases and, as a result, AIDS-related mortality. With the purpose to estimate PCP occurrence and HAART interference, 376 HIV-infected or AIDS patients were studied from January 1992 to December 2002.

From the beginning of the AIDS epidemic, pneumocystis pneumonia (PCP) has been distinguished as one of the most frequent opportunistic diseases with high morbid-mortality. As from 1996, the advent of the highly active antiretroviral therapy (HAART) has changed the characteristics of such epidemic by reducing its related diseases and, as a result, AIDS-related mortality. With the purpose to estimate PCP occurrence and HAART interference, 376 HIV-infected or AIDS patients were studied from January 1992 to December 2002. Among them, 58 (15.5%) PCP cases were found. There was a higher occurrence of PCP in the group of patients in which HAART was not used, with 40 (69.0%) of the episodes. As regards the studied period, a tendency to a linear reduction in annual PCP incidence was observed. The mean of T CD4+ lymphocytes in the patients with PCP (117 cells/mm3) was significantly lower when compared to that of the other individuals (325 cells/mm3). Therefore, this study suggests a temporal reduction in PCP occurrence related to HAART use with higher T CD4+ lymphocyte counts. Nevertheless, this opportunistic infection still shows significant incidence in AIDS patients.

Eligibility Criteria:
Inclusion Criteria:

* HIV infection

Exclusion Criteria:

* No HIV infection
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.

This is a first in human phase 1 multicenter open label study to evaluate the safety and tolerability of AMG 224 in subjects with relapsed or refractory multiple myeloma. The study will be conducted in 2 parts. Part 1 is the dose-exploration and part 2 is the dose-expansion. Study medication will be administered once every 3 weeks by intravenous (IV) infusion.

Eligibility Criteria:
Inclusion Criteria:

- Pathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma.

Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide).

* Willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).
* Measurable disease per the International Myeloma Working Group (IMWG) response criteria
* Hematological function, as follows, without transfusion support:
* Absolute neutrophil count ≥ 1.0 X 10\^9/L,
* Platelet count ≥ 75 X 10\^9/L (in patients with \< 50% of bone marrow nucleated cells were plasma cells) or ≥ 50 X 10\^9/L (in patients with ≥ 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support
* Hemoglobin \> 8 g/dL (\> 80 g/L)
* Adequate renal and hepatic function
* Left ventricular ejection fraction (LVEF) \> 50%

Exclusion Criteria:

* Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
* Autologous stem cell transplant less than 90 days prior to study day 1
* Multiple myeloma with IgM subtype
* POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or Amyloidosis
* Glucocorticoid therapy (prednisone \> 30 mg/day or equivalent) within 7 days prior to study day
* Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association \> class II)
* A baseline ECG QTcF \> 470 msec
* Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days prior to study day 1